GenSight Biologics Announces Publication of 5-Year Outcomes for Patients Treated Unilaterally with LUMEVOQ® Gene Therapy
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 15 2025
0mins
Source: Businesswire
Long-term Efficacy of LUMEVOQ: GenSight Biologics announced that a five-year follow-up study on patients treated with their gene therapy LUMEVOQ for Leber Hereditary Optic Neuropathy (LHON) showed sustained improvement in visual acuity and a good safety profile, indicating the therapy's long-term benefits.
Quality of Life Improvements: The study also reported significant enhancements in self-reported quality of life scores among participants, with 66.1% achieving clinically meaningful visual improvements, highlighting the positive impact of LUMEVOQ on patient well-being.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
